NANBH
MCID: HPT001
MIFTS: 63

Hepatitis C (NANBH)

Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Nephrological diseases, Oral diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Hepatitis C

MalaCards integrated aliases for Hepatitis C:

Name: Hepatitis C 11 75 53 41 43 14 36 71
Hepatitis C Infection 11 14
Chronic Hepatitis C 11 33
Chronic Hcv - [hepatitis C Virus] Infection 33
Chronic Type C Viral Hepatitis 33
Hepatitis C-Related Cirrhosis 33
Hepatitis C Infection Nos 33
Type C Viral Hepatitis 33
Hepatitis C, Chronic 71
Hepatitis Nona Nonb 11
Hepatitis C Chronic 53
Viral Hepatitis C 11
Hepatitis C Nos 33
Hep C Nos 33
Nanbh 11

Classifications:



External Ids:

Disease Ontology 11 DOID:1883
ICD9CM 34 070.7
MeSH 43 D006526
NCIt 49 C3098
SNOMED-CT 68 154349000
ICD11 33 1615937473
UMLS 71 C0019196 C0524910

Summaries for Hepatitis C

MedlinePlus: 41 What is hepatitis C? Hepatitis is inflammation of the liver. Inflammation is swelling that happens when tissues of the body are injured or infected. Inflammation can damage organs. There are different types of hepatitis. One type, hepatitis C, is caused by the hepatitis C virus (HCV). Hepatitis C can range from a mild illness lasting a few weeks to a serious, lifelong illness. Hepatitis C can be acute or chronic: Acute hepatitis C is a short-term infection. The symptoms can last up to 6 months. Sometimes your body is able to fight off the infection and the virus goes away. But for most people, an acute infection leads to chronic infection. Chronic hepatitis C is a long-lasting infection. If it is not treated, it can last for a lifetime and cause serious health problems, including liver damage, cirrhosis (scarring of the liver), liver cancer, and even death. How is hepatitis C spread? Hepatitis C spreads through contact with the blood of someone who has HCV. This contact may be through: Sharing drug needles or other drug materials with someone who has HCV. In the United States, this is the most common way that people get hepatitis C. Getting an accidental stick with a needle that was used on someone who has HCV. This can happen in health care settings. Being tattooed or pierced with tools or inks that were not sterilized after being used on someone who has HCV Having contact with the blood or open sores of someone who has HCV Sharing personal care items that may have come in contact with another person's blood, such as razors or toothbrushes Being born to a mother with HCV Having unprotected sex with someone who has HCV Before 1992, hepatitis C was also commonly spread through blood transfusions and organ transplants. Since then, there has been routine testing of the U.S. blood supply for HCV. It is now very rare for someone to get HCV this way. Who is at risk for hepatitis C? You are more likely to get hepatitis C if you: Have injected drugs Had a blood transfusion or organ transplant before July 1992 Have hemophilia and received clotting factor before 1987 Have been on kidney dialysis Were born between 1945 and 1965 Have abnormal liver tests or liver disease Have been in contact with blood or infected needles at work Have had tattoos or body piercings Have worked or lived in a prison Were born to a mother with hepatitis C Have HIV/AIDS Have had more than one sex partner in the last 6 months Have had a sexually transmitted disease Are a man who has had sex with men If you are at high risk for hepatitis C, your health care provider will likely recommend that you get tested for it. What are the symptoms of hepatitis C? Most people with hepatitis C have no symptoms. Some people with acute hepatitis C do have symptoms within 1 to 3 months after they are exposed to the virus. These symptoms may include: Dark yellow urine Fatigue Fever Gray- or clay-colored stools Joint pain Loss of appetite Nausea and/or vomiting Pain in your abdomen Jaundice (yellowish eyes and skin) If you have chronic hepatitis C, you probably will not have symptoms until it causes complications. This can happen decades after you were infected. For this reason, hepatitis C screening is important, even if you have no symptoms. What other problems can hepatitis C cause? Without treatment, hepatitis C may lead to cirrhosis, liver failure, and liver cancer. Early diagnosis and treatment of hepatitis C can prevent these complications. How is hepatitis C diagnosed? Health care providers diagnose hepatitis C based on your medical history, a physical exam, and blood tests. If you do have hepatitis C, you may need additional tests to check for liver damage. These tests may include other blood tests, an ultrasound of the liver, and a liver biopsy. What are the treatments for hepatitis C? Treatment for hepatitis C is with antiviral medicines. They can cure the disease in most cases. If you have acute hepatitis C, your health care provider may wait to see if your infection becomes chronic before starting treatment. If your hepatitis C causes cirrhosis, you should see a doctor who specializes in liver diseases. Treatments for health problems related to cirrhosis include medicines, surgery, and other medical procedures. If your hepatitis C leads to liver failure or liver cancer, you may need a liver transplant. Can hepatitis C be prevented? There is no vaccine for hepatitis C. But you can help protect yourself from hepatitis C infection by: Not sharing drug needles or other drug materials Wearing gloves if you have to touch another person's blood or open sores Making sure your tattoo artist or body piercer uses sterile tools and unopened ink Not sharing personal items such toothbrushes, razors, or nail clippers Using a latex condom during sex. If your or your partner is allergic to latex, you can use polyurethane condoms. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary: Hepatitis C, also known as hepatitis c infection, is related to hepatitis c virus and viral infectious disease, and has symptoms including vomiting, fatigue and fever. An important gene associated with Hepatitis C is MIR122 (MicroRNA 122), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Translation Insulin regulation of translation. The drugs Ezetimibe and Levoleucovorin have been mentioned in the context of this disorder. Affiliated tissues include Blood, liver and kidney, and related phenotypes are Reduced mammosphere formation and Increased JFH-1 genotype 2a Hepatitis C virus (HCV) infection

Disease Ontology: 11 A viral infectious disease that results in inflammation located in liver, has material basis in Hepatitis C virus, which is transmitted by blood from an infected person enters the body of an uninfected person. The infection has symptom fever, has symptom fatigue, has symptom loss of appetite, has symptom nausea, has symptom vomiting, has symptom abdominal pain, has symptom clay-colored bowel movements, has symptom joint pain, and has symptom jaundice.

Wikipedia: 75 Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV) that primarily affects the... more...

Related Diseases for Hepatitis C

Diseases in the Hepatitis family:

Hepatitis C Virus Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis B Hepatitis D
Autoimmune Hepatitis Hepatitis E
Autoimmune Hepatitis Type 2 Autoimmune Hepatitis Type 1

Diseases related to Hepatitis C via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1603)
# Related Disease Score Top Affiliating Genes
1 hepatitis c virus 33.3 STAT3 SCARB1 PI4KA HM13 GPT EIF2AK2
2 viral infectious disease 32.8 MIR122 IFNA2 IFNA1 GPT EIF2AK2 CLEC4M
3 cryoglobulinemia, familial mixed 32.8 IFNA2 IFNA1
4 viral hepatitis 32.7 MIR122 IFNA2 IFNA1 HFE GPT GGT1
5 hepatitis b 32.6 STAT3 IFNA2 IFNA1 GPT GGT1 EIF2AK2
6 hepatitis a 32.6 IFNA2 IFNA1 GPT
7 liver disease 32.5 MIR122 MAPK8 IFNA2 IFNA1 HFE GPT
8 cryoglobulinemia 32.4 IFNA2 IFNA1 GPT CD81
9 hepatitis 32.4 STAT3 SCARB1 PI4KA MAPK8 JAK1 IFNA2
10 liver cirrhosis 32.3 MIR122 IFNA1 HOTAIR HFE GPT GGT1
11 non-alcoholic fatty liver disease 32.2 SCARB1 MIR122 MAPK8 HFE GPT GGT1
12 immune deficiency disease 32.0 MIR122 MAPK8 IFNA1 GPT EIF2AK2 CLEC4M
13 alcohol use disorder 32.0 HFE GPT GGT1
14 fatty liver disease 32.0 STAT3 SCARB1 MIR122 MAPK8 HFE GPT
15 deficiency anemia 31.8 IFNA2 IFNA1 HFE GRB2 GPT
16 thrombocytopenia 31.8 STAT3 IFNA2 IFNA1 GPT GGT1 APOE
17 non-alcoholic steatohepatitis 31.7 SCARB1 MIR122 GPT
18 hepatitis d 31.7 IFNA2 IFNA1 GPT EIF2AK2
19 type 2 diabetes mellitus 31.6 STAT3 SCARB1 MIR122 MAPK8 HFE GPT
20 hepatocellular carcinoma 31.6 STAT3 MIR122 MAPK8 JAK1 IFNA2 IFNA1
21 splenomegaly 31.6 IFNA2 IFNA1 APOE
22 beta-thalassemia 31.6 IFNA1 HFE GPT APOE
23 alcoholic liver cirrhosis 31.5 HFE GPT GGT1
24 peripheral nervous system disease 31.5 STAT3 MIR122 IFNA1 HFE GPT APOE
25 hepatitis e 31.4 MIR122 GRB2 GPT
26 hypothyroidism 31.4 IFNA2 IFNA1 GPT APOE
27 stomatitis 31.4 IFNA2 IFNA1 EIF2AK2
28 lipid metabolism disorder 31.3 SCARB1 GPT GGT1 APOE
29 siderosis 31.2 HFE GPT APOE
30 diabetes mellitus 31.2 STAT3 SCARB1 MIR122 MAPK8 HFE GPT
31 celiac disease 1 31.2 STAT3 IFNA1 HFE GPT
32 severe acute respiratory syndrome 31.1 IFNA1 GPT CLEC4M
33 skin sarcoidosis 31.0 JAK1 IFNA1
34 cardiovascular system disease 31.0 STAT3 SCARB1 MIR122 GGT1 APOE
35 hyperuricemia 31.0 GPT GGT1 APOE
36 herpes zoster 31.0 JAK1 IFNA2 IFNA1 APOE
37 hypereosinophilic syndrome 31.0 STAT3 JAK1 IFNA2 IFNA1
38 behcet syndrome 30.9 STAT3 JAK1 IFNA2 IFNA1
39 wilson disease 30.8 MIR122 HFE GPT
40 measles 30.8 STAT3 JAK1 IFNA1 EIF2AK2
41 severe covid-19 30.7 IFNA2 IFNA1 GPT
42 cholelithiasis 30.7 SCARB1 GPT APOE
43 body mass index quantitative trait locus 11 30.7 STAT3 SCARB1 MIR122 MAPK8 HFE GPT
44 obstructive jaundice 30.6 MIR122 GPT GGT1
45 dengue hemorrhagic fever 30.6 IFNA1 GPT CLEC4M
46 malaria 30.5 SCARB1 IFNA2 IFNA1 GPT CD81 APOE
47 polycythemia vera 30.5 STAT3 JAK1 IFNA2 IFNA1
48 skin disease 30.5 STAT3 MIR122 JAK1 IFNA1 GPT
49 primary cutaneous t-cell non-hodgkin lymphoma 30.5 STAT3 IFNA2 IFNA1
50 dengue shock syndrome 30.4 IFNA1 GPT CLEC4M

Graphical network of the top 20 diseases related to Hepatitis C:



Diseases related to Hepatitis C

Symptoms & Phenotypes for Hepatitis C

Symptoms:

11
  • vomiting
  • fatigue
  • fever
  • jaundice
  • abdominal pain
  • nausea
  • loss of appetite
  • joint pain
  • clay-colored bowel movements

GenomeRNAi Phenotypes related to Hepatitis C according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 EIF2AK2 GGT1 GRB2 HFE MAPK8 PI4KA
2 Increased JFH-1 genotype 2a Hepatitis C virus (HCV) infection GR00233-A-1 8.65 HM13

MGI Mouse Phenotypes related to Hepatitis C:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.28 APOE CD81 CLEC4M DDX3X EIF2AK2 GGT1
2 growth/size/body region MP:0005378 10.22 APOE CD81 DDX3X EIF2AK2 GGT1 GRB2
3 immune system MP:0005387 10.16 APOE CD81 CLEC4M EIF2AK2 GGT1 GRB2
4 endocrine/exocrine gland MP:0005379 10.11 APOE DDX3X GGT1 GRB2 HM13 JAK1
5 renal/urinary system MP:0005367 10.08 APOE CLEC4M GGT1 GRB2 HM13 JAK1
6 liver/biliary system MP:0005370 10.06 APOE HFE HM13 JAK1 MAPK8 MIR122
7 digestive/alimentary MP:0005381 9.92 APOE CLEC4M GRB2 HFE HM13 MAPK8
8 respiratory system MP:0005388 9.76 APOE CD81 HM13 IFNA1 IFNA2 JAK1
9 skeleton MP:0005390 9.7 APOE CD81 GGT1 GPT GRB2 HFE
10 hematopoietic system MP:0005397 9.53 APOE CD81 CLEC4M EIF2AK2 GGT1 GRB2

Drugs & Therapeutics for Hepatitis C

Drugs for Hepatitis C (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 413)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ezetimibe Approved Phase 4 163222-33-1 150311
2
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
3
Acarbose Approved, Investigational Phase 4 56180-94-0 441184 444254
4
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
5
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
6
Nevirapine Approved Phase 4 129618-40-2 4463
7
Metformin Approved Phase 4 1115-70-4, 657-24-9 4091
8
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
9
Nitazoxanide Approved, Investigational, Vet_approved Phase 4 55981-09-4 41684
10
Lopinavir Approved Phase 4 192725-17-0 92727
11
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
12
Zidovudine Approved Phase 4 30516-87-1 35370
13
Fosamprenavir Approved Phase 4 226700-79-4 131536
14
Colchicine Approved Phase 4 64-86-8 2833 6167
15
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
16
Promethazine Approved, Investigational Phase 4 60-87-7 4927
17
Cobicistat Approved Phase 4 1004316-88-4 24950485 25151504
18
Elvitegravir Approved Phase 4 697761-98-1 23083982 5277135
19
Citalopram Approved Phase 4 59729-32-7, 59729-33-8 2771
20
Iron Approved Phase 4 7439-89-6 29936
21
Losartan Approved Phase 4 114798-26-4 3961
22
Atorvastatin Approved Phase 4 134523-00-5 60823
23
Chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
24
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
25
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030
26
Didanosine Approved Phase 4 69655-05-6 50599
27
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
28
Nelfinavir Approved Phase 4 159989-64-7 64143
29
Baclofen Approved Phase 4 1134-47-0 2284
30
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
31
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
32
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
33
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
34
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
35
Pancrelipase Approved, Investigational Phase 4 53608-75-6 8519
36
Mecobalamin Approved, Investigational Phase 4 13422-55-4
37
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 44475014
38
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7, 53152-21-9 644073 40400
39
Methadone Approved Phase 4 76-99-3, 1095-90-5 4095
40
Mycophenolic acid Approved, Investigational Phase 4 24280-93-1 446541
41
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
42
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
43
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
44
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
45
Histamine Approved, Investigational Phase 4 51-45-6 774
46
Cathine Approved, Experimental, Illicit, Vet_approved, Withdrawn Phase 4 14838-15-4, 492-39-7 131954576 4786 26934
47
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
48
Rosiglitazone Approved, Investigational Phase 4 122320-73-4, 155141-29-0 77999
49
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239
50
Modafinil Approved, Investigational Phase 4 68693-11-8 4236

Interventional clinical trials:

(show top 50) (show all 2334)
# Name Status NCT ID Phase Drugs
1 Hepatitis C in Renal Transplant Recipients - Safety and Efficacy of a Conversion of Immunosuppression to High-dose Cyclosporine A and Its Impact on Hepatitis C Virus-replication, Parameters of Liver Function and Glucose Tolerance. An Open Label Trial. Unknown status NCT02108301 Phase 4 tacrolimus-cyclosporine A
2 The Response and Outcomes of Pegylated Interferon Plus Ribavirin Combination Therapy for Chronic Hepatitis C Patients Concomitant With Hepatocellular Carcinoma Unknown status NCT00834860 Phase 4 peginterferon alpha-2a and ribavirin
3 An Efficacy and Safety Study Comparing Pegylated-Interferon and Ribavirin Plus Metformin to Pegylated-Interferon and Ribavirin in the Treatment of naïve Patients With Genotype 1 Chronic HCV Infection and Insulin Resistance Unknown status NCT00370617 Phase 4 metformin
4 Pilot Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection in Liver Transplant Candidates (EZE-2) Unknown status NCT02768545 Phase 4 Ezetimibe
5 A Phase 4, Open-Label Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease Unknown status NCT02691728 Phase 4 LDV/SOF FDC
6 A Single Center, Prospective Phase IV, Open-Label, Randomized Trial Comparing the Efficacy , Tolerability, and Safety of Quadritherapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide + Alfacalcidol ( Bon-One ®) ) Versus Triple Therapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide) Versus the Standard of Care Regimen(Reiferon Retard® + Ribavirin) in the Treatment of Naïve Chronic Hepatitis- C Among the Egyptian Population. Effectiveness Will be Evaluated Based on Sustained Viral Response (SVR) Unknown status NCT01896609 Phase 4 Bon one in Arm 3;Xerovirinc in Arm 2;Ribavirin in Arm 1
7 Simplifying Hepatitis C Antiviral Therapy in Rwanda for Elsewhere in the Developing World: Pangenotypic and Retreatment Study (SHARED3) Unknown status NCT03888729 Phase 4 sofosbubir/velpatasvir;sofosbubir/velpatasvir/voxilaprevir
8 Localized on -Site Testing and Treatment of Hepatitis C in Homeless Persons in South London: a Pilot Non-randomised Phase 4 Interventional Clinical Trial of Grazoprevir and Elbasvir ± Ribavirin in Participants With Genotype 1a, 1b or 4 to Measure Efficacy and Adherence to Treatment in a Homeless Population Unknown status NCT03797066 Phase 4 ZEPATIER 50Mg-100Mg Tablet
9 Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination Therapy in Treatment of Chronic Hepatitis C Infection in Egyptian Children With Gaucher Disease Unknown status NCT03721627 Phase 4 Ledipasvir/Sofosbuvir
10 Personalized Medicine in HCV Infection: Cognitive Impairments and Brain Anomalies in Chronic Hepatitis C Infected Individuals. Characterization and Potential Reversibility With Direct Antiviral Agents. Unknown status NCT02745132 Phase 4
11 Direct Observed Therapy With Ledipasvir/Sofosbuvir in Treatment-naïve Patients With Chronic Genotype 1 HCV (Hepatitis C Virus) Infection Receiving Opiate Substitution Therapy Unknown status NCT02638233 Phase 4 Sofosbuvir 400mg / Ledipasvir 90 mg (FDC)
12 Open, Multicentre,Randomized Phase IV Trial to Evaluate Efficacy/Safety to Extend Treatment Duration With Peginterferon Alfa-2a+High Dose of Ribavirin Supporting Epo β in Treatment of CHC in HIV-HCV Patients Who Not Clear Virus at Week 4 Unknown status NCT00526448 Phase 4 ribavirin;Peginterferon alfa-2a;epoetin beta
13 Efficacy and Safety of Daclatasvir Plus Asunaprevir Treatment in Patients With Chronic Hepatitis C : Prospective Cohort Study Unknown status NCT02639585 Phase 4 Daclinza and Sunvepra
14 Curing HCV in Incarcerated Patients Unknown status NCT03018353 Phase 4 Patients receiving Sof/Vel (Epclusa) and Navigation services
15 Safety and Effect of Elbasvir/Grazoprevir Combination Therapy in Hemodialysis Patients With Chronic Hepatitis C Unknown status NCT03022006 Phase 4 elbasvir, grazoprevir
16 A Monocenter Randomized Double-blind Placebo-controlled Study to Investigate Neuropsychiatric Manifestations of HCV-infection During and After Treatment With Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Unknown status NCT03003338 Phase 4 OBV/PTV/r and DSV;Placebo to match OBV/PTV/r and DSV
17 Randomized, Multi-Center, Partially Placebo-Controlled Phase IV-Study to Compare Efficacy and Tolerability of 48-Week Combined Therapy With Peginterferon Alfa-2a, Ribavirin and Amantadine Sulphate Versus Placebo in Untreated Patients With Chronic Hepatitis C Virus-Genotype-1-Infection Unknown status NCT00127777 Phase 4 Amantadine sulphate (in addition to standard treatment)
18 Open, Randomized and Multicenter Phase IV Study to Compare the Efficacy and Safety of Two Different Treatments Duration 24 Versus 48 Weeks in Chronic Hepatitis C Genotypes 2 and/or 3 co-Infected HIV-HCV Patients. Unknown status NCT00611819 Phase 4 Peg interferon + Ribavirin
19 Efficacy and Safety of a Hansenula-derived Pegylated Interferon α2a (Reiferon Retard®) in Treatment of Patients With Chronic Hepatitis C Virus Infection: A National Multi-center Phase IV Open Label Non-Randomized Trial Unknown status NCT01649245 Phase 4 Reiferon retard
20 Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Switch Followed by Sofosbuvir/Velpatasvir (SOF/VEL) Antiviral HCV Therapy Followed by Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Simplification in HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy - A Pilot Feasibility Study Unknown status NCT03549312 Phase 4 Genvoya;Epclusa;Biktarvy
21 An Open-label, Multi-center, Randomized Study Comparing the Effects of Oral Hypoglycemic Agents on Viral Kinetics of Chronic Hepatitis C Patients Receiving Pegylated Interferon Alfa 2b Plus Ribavirin Unknown status NCT01025765 Phase 4 Pioglitazone;Acarbose;Metformin
22 Treatment of Chronic Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels With Peginterferon α-2a (40 kDa) Plus Ribavirin Unknown status NCT00575627 Phase 4 Peg-Interferon alpha2a plus Ribavirin
23 A Prospective Randomized, Open Labeled, Phase IV, Multicenter Study for Peginterferon Alfa-2a and Weight-based Ribavirin for 16 or 24 Weeks in genotype2 Chronic Hepatitis C Patients Who Achieved Rapid Virologic Response Unknown status NCT01056172 Phase 4 Peginterferon alfa-2a and Ribavirin
24 A Pilot Study to Treat Patients With Chronic HCV Genotype 1 and ESRD Receiving Hemodialysis and Naïve to Prior HCV Therapy With Peginterferon Alfa-2b, the Maximally Tolerated Ribavirin Dose and Boceprevir Unknown status NCT01731301 Phase 4 Ribavirin;Peginterferon;Boceprevir
25 A Randomized, Multi-center, Phase IV Open-label Study Evaluating the Antiviral Efficacy of Addition of Vitamin D in Patients With Treatment Naïve Chronic Hepatitis C Receiving Peginterferon Alfa-2a Plus Ribavirin Unknown status NCT01439776 Phase 4
26 An Open Label, Randomized, Parallel Design Estimation Pilot Study to Compare the Effectiveness of 36 vs 48 Wks PegIntron Plus Ribavirin Treatment for HCV Patients Without Rapid Virologic Response(RVR) But With Undetectable HCV RNA at wk 8 Unknown status NCT01683786 Phase 4 Pegintron + Riba
27 Screening for Hepatitis C and Hepatitis B in Inpatients: A Toronto Viral Hepatitis Care Network (VIRCAN) Collaboration Unknown status NCT04620226 Phase 4
28 A Phase IV, Single Arm, Open-Label Study to Determine the Efficacy and Safety of Ledipasvir/Sofosbuvir (LDV/SOF) in Treatment-Naive Alcoholic Subjects With Chronic Genotype 1 Hepatitis C Infection Unknown status NCT02759861 Phase 4 harvoni
29 The Effects of Preventive Versus on Demand Nutritional Advice and Support on the Nutritional Status of Patients During Antiviral Therapy for Hepatitis C A Randomized, Multi Center Trial Unknown status NCT00841243 Phase 4
30 Telaprevir in Patients With Genotype 3 HCV: Pilot Clinical Study to Evaluate Efficacy and Predictability of Therapy in Patients Who Have Failed to Respond to Pegylated Interferon and Ribavirin Unknown status NCT02087111 Phase 4 Telaprevir;40 Kd Pegylated interferon alfa 2a;Ribavirin
31 Expression of Inflammasomes in HCV Patients Before and After Treatment Unknown status NCT04244383 Phase 4
32 Grazoprevir/Elbasvir for Treatment of Hepatitis C Virus Genotype 4 Post Kidney Transplant Unknown status NCT03359746 Phase 4 Grazoprevir/Elbasvir
33 The Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination for Treatment of Egyptian Children and Adolescents With Chronic Hepatitis C (HCV)-Genotype 4 Unknown status NCT03743727 Phase 4 Combined therapy LDV and SOF
34 An Open-Label Study to Evaluate Long-Term Outcomes With Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Fertile Women With Genotype 1 and 4 Chronic Hepatitis C Virus (HCV) Infection Unknown status NCT02950870 Phase 4 Ombitasvir-Paritaprevir-Ritonavir;Dasabuvir;Ribavirin
35 Toward Elimination of Hepatitis C Virus (HCV): A Pilot Study Combining HCV and Addiction Treatment of Young Suburban Heroin Users (SHU) That Addresses Barriers to Care Unknown status NCT03364725 Phase 4 Glecaprevir-pibrentasvir
36 Personalized Medicine in HCV Chronic Infection. Endothelial Dysfunction and Subclinical Atheromatosis in Patients With HCV Infection. Characterization and Potential Reversibility With Direct Antiviral Agents. Unknown status NCT02802280 Phase 4
37 Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment: A Pilot Project Unknown status NCT02460133 Phase 4 Paritaprevir;Ritonavir;Dasabuvir;Ombitasvir;Ribavirin
38 An Open-label, Randomised Pilot Study Comparing the Efficacy, Safety and Tolerability of Raltegravir With Protease Inhibitor-based Therapy in Treatment-naïve, HIV/Hepatitis C Co-infected Injecting Drug Users Receiving Methadone Unknown status NCT01105611 Phase 4 Raltegravir;Atazanavir/Ritonavir
39 A Pilot Study to Assess the Efficacy and Safety of Folic Acid and/or Vitamin B Complex on Hepatitis C Infected Patients Treated With Pegylated Interferon and Ribavirin. Unknown status NCT02150291 Phase 4 Neurobion;placebo
40 the Prevalence of Acute Kidney Injury in Patients With Chronic Hepatitis c Virus Receiving Sofuspovir Containing Direct Acting Antiviral Therapy Unknown status NCT04267458 Phase 4
41 Effect Of Interferon-Free Direct Acting Antiviral Agents For Treatment Of Hepatitis C Virus Patients On The Normal Kidney Unknown status NCT03296930 Phase 4 Sofosbuvir 400 MG Oral Tablet,;Ombitasvir/paritaprevir/ritonavir
42 Efficacy of Pentoxyfylline Addition to a Treatment Scheme Based on Interferon Alpha and Ribavirin on Hepatitis C Virus Coinfected HIV Patients, Considering Interleukin 28B Polymorphism rs12979860 Unknown status NCT02008214 Phase 4 Pentoxifylline;Placebo
43 Phase IV Study of Effectiveness of Interferon and Ribavirin Treatment in Thalassemia Major Patients With Chronic Viral Hepatitis C Unknown status NCT00887081 Phase 4 PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin
44 A Single-center Pilot Study of the Use of Hepatitis C Positive Donors for Hepatitis C Negative Heart Transplant Recipients With Post-transplant Treatment of Hepatitis C Viremia With Mavyret Completed NCT03382847 Phase 4
45 Bridging Care to HCV Treatment Among Opiate Dependent Patients on Buprenorphine/Naloxone Maintenance Therapy: A Pilot Study of Treating HCV With Epclusa at a Psychiatrist-staffed Outpatient Addiction Clinic Completed NCT03235154 Phase 4 sofosbuvir/velpatasvir
46 Towards HCV Elimination: Evaluation of an Integrated Model of HCV Care Targeting People Who Inject Drugs in Hai Phong, Vietnam Completed NCT03537196 Phase 4 Sofosbuvir 400 mg and Daclatasvir 60 mg;Sofosbuvir 400 mg and Daclatasvir 90 mg;Ribavirin;Sofosbuvir and Daclatasvir for 24 weeks
47 An Open-label Pilot Study to Determine the Tolerability and Efficacy of Fixed-dose Grazoprevir/Elbasvir Treatment in Hepatitis C Uninfected Recipients of Renal Transplants From Hepatitis C Infected Deceased Donors Completed NCT02781649 Phase 4 Zepatier;Ribavirin;Sofosbuvir
48 A Study of the Antiviral Activity of Metformin as an Anti-Hepatitis C Virus Agent in Patients With Chronic Hepatitis C Virus Infection Completed NCT02972723 Phase 4 Metformin
49 A Randomized, Open-label Study of Prophylactic Administration of PEGASYS Plus Ribavirin After Liver Transplantation on Hepatitis C Recurrence in Patients With Hepatitis C Completed NCT00087633 Phase 4 peginterferon alfa-2a [Pegasys];Copegus
50 A Prospective, Multicenter, Open-label, Comparative, Efficacy Study of Pegasys® Plus Copegus® in Treatment-naïve Latino Patients With Chronic Hepatitis C-genotype 1, as Compared to Treatment-naïve Non- Latino Caucasian Patients With Chronic Hepatitis C-genotype 1 Completed NCT00107653 Phase 4 Ribavirin;Peginterferon alfa-2a

Search NIH Clinical Center for Hepatitis C

Inferred drug relations via UMLS 71 / NDF-RT 50 :


boceprevir
daclatasvir
dasabuvir
elbasvir
grazoprevir
Hepatitis C Virus Non-Nucleoside NS5B Palm Polymerase Inhibitor [EPC]
Hepatitis C Virus NS3/4A Protease Inhibitor [EPC]
Hepatitis C Virus NS5A Inhibitor [EPC]
Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC]
Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
ledipasvir
ombitasvir
paritaprevir
PEGINTERFERON
peginterferon alfa-2a
peginterferon alfa-2b
Recombinant interferon beta-1a
Recombinant interferon beta-1b
Ribavirin
simeprevir
sofosbuvir
telaprevir
velpatasvir

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hepatitis C cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Hepatitis C:
Autologous hematopoietic stem cells for treatment of end-stage chronic liver disease
Embryonic/Adult Cultured Cells Related to Hepatitis C:
Peripheral blood-derived hematopoietic stem cells PMIDs: 20587151

Cochrane evidence based reviews: hepatitis c

Genetic Tests for Hepatitis C

Anatomical Context for Hepatitis C

Organs/tissues related to Hepatitis C:

FMA: Liver
MalaCards : Liver, Kidney, Skin, T Cells, Bone Marrow, Myeloid, Heart
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Hepatitis C:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate

Publications for Hepatitis C

Articles related to Hepatitis C:

(show top 50) (show all 44168)
# Title Authors PMID Year
1
Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. 62 46
19122656 2009
2
Executive Summary of the KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. 41
36411019 2022
3
KDIGO 2022 Clinical Practice Guideline FOR the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. 41
36410841 2022
4
Primary Care Evaluation of a Hepatitis C Virus (HCV) Screening Education Intervention. 41
36257701 2022
5
Relationship between serum concentrations of keratin-18 and apoptosis in chronic hepatitis C. 53 62
20374042 2010
6
Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. 53 62
20235331 2010
7
Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. 53 62
20357091 2010
8
Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. 53 62
20186843 2010
9
Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia. 53 62
20169624 2010
10
The scavenger receptors SRA-1 and SREC-I cooperate with TLR2 in the recognition of the hepatitis C virus non-structural protein 3 by dendritic cells. 53 62
20338659 2010
11
HFE mutations in alpha-1-antitrypsin deficiency: an examination of cirrhotic explants. 53 62
20208481 2010
12
Clinical trial: the efficacy and safety of oral PF-03491390, a pancaspase inhibitor - a randomized placebo-controlled study in patients with chronic hepatitis C. 53 62
20163376 2010
13
Disease progression from chronic hepatitis C to cirrhosis and hepatocellular carcinoma is associated with repression of interferon regulatory factor-1. 53 62
19858727 2010
14
Natural killer cell receptor and HLA-C gene polymorphisms among patients with hepatitis C: a comparison between sustained virological responders and non-responders. 53 62
20456039 2010
15
Association between lipoprotein subfraction profile and the response to hepatitis C treatment in Japanese patients with genotype 1b. 53 62
19708862 2010
16
Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic Fatty liver disease. 53 62
19881359 2010
17
Circulating Toll-like receptor (TLR) 2, TLR4, and regulatory T cells in patients with chronic hepatitis C. 53 62
20402671 2010
18
Core-specific adaptive regulatory T-cells in different outcomes of hepatitis C. 53 62
20222873 2010
19
R753Q single-nucleotide polymorphism impairs toll-like receptor 2 recognition of hepatitis C virus core and nonstructural 3 proteins. 53 62
20090572 2010
20
Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus. 53 62
20077564 2010
21
The role of iron overload and HFE gene mutations in the era of pegylated interferon and ribavirin treatment of chronic hepatitis C. 53 62
20190684 2010
22
Significance of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in chronic hepatitis C patients. 53 62
20350877 2010
23
Association among Fas expression in leucocytes, serum Fas and Fas-ligand concentrations and hepatic inflammation and fibrosis in chronic hepatitis C. 53 62
19919570 2010
24
Effect of ribavirin on the frequency of RNase L cleavage sites within the hepatitis C viral genome. 53 62
19758279 2010
25
Associations among behavior-related susceptibility factors in porphyria cutanea tarda. 53 62
19948245 2010
26
Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders. 53 62
19709362 2010
27
Hepatitis C virus-induced up-regulation of protein phosphatase 2A inhibits histone modification and DNA damage repair. 53 62
20043320 2010
28
Dendritic cell inhibition is connected to exhaustion of CD8+ T cell polyfunctionality during chronic hepatitis C virus infection. 53 62
20173023 2010
29
Clinical significance of alanine aminotransferase levels and the effect of ursodeoxycholic acid in hemodialysis patients with chronic hepatitis C. 53 62
19890604 2010
30
Tissue and serum immune response in chronic hepatitis C with mild histological lesions. 53 62
20209325 2010
31
Hepatic steatosis in hepatitis C is a storage disease due to HCV interaction with microsomal triglyceride transfer protein (MTP). 53 62
20178560 2010
32
Serum cytokine profile in hepatitis C virus carriers presenting cryoglobulinaemia and non-organ-specific autoantibodies. 53 62
20005287 2010
33
Impaired antiviral activity of interferon alpha against hepatitis C virus 2a in Huh-7 cells with a defective Jak-Stat pathway. 53 62
20149251 2010
34
ISG15, a ubiquitin-like interferon-stimulated gene, promotes hepatitis C virus production in vitro: implications for chronic infection and response to treatment. 53 62
19846672 2010
35
Human leukocyte antigen alleles and the response to pegylated interferon/ribavirin therapy in chronic hepatitis C patients. 53 62
19931565 2010
36
Retinol supplements antiviral action of interferon in patients with chronic hepatitis C: a prospective pilot study. 53 62
20104263 2010
37
Virological rather than host factors are associated with transaminase levels among HIV/HCV-coinfected patients. 53 62
20071593 2010
38
Occult hepatitis B virus infection: a covert operation. 53 62
20002296 2010
39
Enhanced RIG-I expression is mediated by interferon regulatory factor-2 in peripheral blood B cells from hepatitis C virus-infected patients. 53 62
20034464 2010
40
Hepatitis C virus core protein subverts the antiviral activities of human Kupffer cells. 53 62
19769973 2010
41
Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants. 53 62
19828610 2010
42
Serum concentrations of interleukin 1beta, CXCL10, and interferon-gamma in mixed cryoglobulinemia associated with hepatitis C infection. 53 62
19918044 2010
43
Protease and helicase activities of hepatitis C virus genotype 4, 5, and 6 NS3-NS4A proteins. 53 62
19944069 2010
44
[Investigation of the relationship between hepatitis c virus (HCV) genotypes with HCV-RNA and alanine aminotransferase levels in chronic hepatitis c patients]. 53 62
20455406 2010
45
Alteration of serum thrombopoietin levels in patients with chronic hepatitis C under interferon therapy. 53 62
20203368 2010
46
Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition. 53 62
19782079 2010
47
Ketoprofen, peginterferon 2a and ribavirin for genotype 1 chronic hepatitis C: a phase II study. 53 62
20014458 2009
48
Hepatoma cell density promotes claudin-1 and scavenger receptor BI expression and hepatitis C virus internalization. 53 62
19776133 2009
49
Lovastatin and fluvastatin reduce viremia and the pro-inflammatory cytokines in the patients with chronic hepatitis C. 53 62
20214221 2009
50
Serum alpha-fetoprotein levels during and after interferon therapy and the development of hepatocellular carcinoma in patients with chronic hepatitis C. 53 62
19093203 2009

Variations for Hepatitis C

Expression for Hepatitis C

Search GEO for disease gene expression data for Hepatitis C.

Pathways for Hepatitis C

Pathways related to Hepatitis C according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.16 STAT3 MAPK8 JAK1 IFNA2 IFNA1 GRB2
2
Show member pathways
12.61 STAT3 MAPK8 JAK1 GRB2 EIF2AK2
3
Show member pathways
12.38 JAK1 IFNA2 IFNA1 EIF2AK2
4
Show member pathways
12.38 STAT3 MAPK8 JAK1 GRB2 EIF2AK2
5
Show member pathways
12.36 STAT3 MAPK8 JAK1 GRB2
6
Show member pathways
12.11 STAT3 MAPK8 GRB2 EIF2AK2
7
Show member pathways
12.02 STAT3 MAPK8 JAK1
8
Show member pathways
12 STAT3 MAPK8 JAK1 IFNA2 IFNA1 GRB2
9
Show member pathways
11.85 STAT3 MAPK8 GRB2
10 11.82 STAT3 MAPK8 GRB2
11 11.72 JAK1 IFNA2 IFNA1
12 11.58 JAK1 MAPK8 STAT3
13
Show member pathways
11.54 MAPK8 JAK1 IFNA2 EIF2AK2
14
Show member pathways
11.51 STAT3 JAK1 GRB2
15
Show member pathways
11.43 GRB2 JAK1 STAT3
16 11.32 STAT3 JAK1 GRB2
17
Show member pathways
11.31 GRB2 JAK1 MAPK8 STAT3
18 11.3 STAT3 JAK1 GRB2
19 11.2 STAT3 MAPK8 JAK1 GRB2
20 11.18 JAK1 IFNA2 EIF2AK2
21 11.1 STAT3 JAK1 GRB2
22 11.05 STAT3 MAPK8 GRB2
23
Show member pathways
10.91 STAT3 JAK1 GRB2 EIF2AK2
24 10.87 STAT3 JAK1

GO Terms for Hepatitis C

Biological processes related to Hepatitis C according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.92 STAT3 JAK1 IFNA2 IFNA1
2 receptor-mediated virion attachment to host cell GO:0046813 9.56 CLEC4M CD81
3 high-density lipoprotein particle clearance GO:0034384 9.46 SCARB1 APOE
4 type I interferon-mediated signaling pathway GO:0060337 9.43 JAK1 IFNA2 IFNA1
5 cellular response to virus GO:0098586 9.23 JAK1 IFNA2 IFNA1 DDX3X

Molecular functions related to Hepatitis C according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 9.56 STAT3 MAPK8 JAK1 GRB2
2 cytokine receptor binding GO:0005126 8.92 JAK1 IFNA2 IFNA1

Sources for Hepatitis C

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....